Affiliation:
1. Nephrology Unit, University Hospital 'Magna Graecia', Department of Medical and Surgical Sciences, Catanzaro, Italy
Abstract
Introduction: The early suspension of Altitude trial in recent years has induced most nephrologists
and cardiologists to abandon Aliskiren use. Consequently, the potential usefulness of the direct
renin inhibition in IgA glomerulonephritis remained an under-investigated therapeutic option.
</P><P>
Case Report: We report the case of a 53 years old IgA GMN patient unresponsive to all conventional
anti-angiotensin-2 agents, steroids and immunosuppressants, in which the administration of Aliskiren
permitted to achieve and maintain a complete proteinuria remission in the absence of any adverse
event.
Conclusion:
Aliskiren might represent a valid and safe therapeutic option in IgA GMN, although further
investigations would be needed to confirm this conclusion.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,General Medicine
Reference41 articles.
1. Hill NR, Fatoba ST, Oke JL. Global prevalence of chronic kidney disease - A Systematic review and meta-analysis.
2. Simeoni M, Cianfrone P, Comi N. Is it feasible to improve
the duration and the efficiency of Ramipril anti-proteinuric response?.
3. D’Onofrio G, Simeoni M, Rizza P. Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients.
4. Tomino Y. Diagnosis and treatment of patients with IgA nephropathy in Japan.
5. Cheng J, Zhang X, Zhang W. Efficacy and safety of glucocorticoids therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献